Left ventricular diastolic function improving agent

摘要

Provided is the use of 4-[(2-{ (2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl} ethyl)thio]butanoic acid for the treatment of heart failure and its symptoms. Further provided are pharmaceutical compositions in the form of injectable solutions and tablets comprising 4-[(2-{ (2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxy-1-buten-1-yl]-5-oxo-1-pyrrolidinyl} ethyl)thio]butanoic acid.